Thyroxine-derivatives of lipopeptides: Bifunctional dimerization inhibitors of human immunodeficiency virus-1 protease

Biochemical Pharmacology

Volumn 65, Issue 7, 2003, Pages 1097-1102

  Dumond, Julien ^a   Boggetto, Nicole ^a   Schramm, Hans J ^b   Schramm, Wolfgang ^b   Takahashi, Masayuki ^c   Reboud Ravaux, Michèle ^a  

^a INSTITUT JACQUES MONOD   (France)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITÉ DE NANTES   (France)

Author keywords

AIDS; Antiproteases; Dimerization inhibitors; HIV 1 protease; Lipopeptides; Thyroxine

Indexed keywords

2 AMINOPALMITIC ACID; 8 ANILINO 1 NAPHTHALENESULFONIC ACID; LIPOPEPTIDE; PALMITIC ACID DERIVATIVE; PROTEINASE INHIBITOR; THYRONINE; THYROXINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BETA SHEET; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DIMERIZATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROPHOBICITY; KINETICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING;

EID: 0037378406     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(02)01622-2     Document Type: Article

References (28)

1. de Clercq E. Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. J. Med. Chem. 38:1995;2491-2517.
2. Carr A., Samaras K., Chisholm D.J., Cooper D.A. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 352:1998;1881-1883.
3. Maschera B., Darby G., Palu G., Wright L.L., Tisdale M., Myers R., Blair E.D., Furfine E.S. Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex. J. Biol. Chem. 271:1996;33231-33235.
4. Wainberg M.A., Friedland G. Public health implications of anti-retroviral therapy and drug resistance. J. Am. Med. Assoc. 279:1998;1977-1983.
5. Gustchina A., Weber I.T. Comparative analysis of the sequences and structures of HIV-1 and HIV-2 proteases. Proteins. 10:1991;325-339.
6. Wlodawer A., Erickson J.W. Strucure-based inhibitors of HIV-1 protease. Annu. Rev. Biochem. 62:1993;543-585.
7. Todd M.J., Semo M., Freire E. The structural stability of HIV-1 protease. J. Mol. Biol. 283:1998;475-488.
8. Schramm H.J., Nakashima H., Schramm W., Wakayama H., Yamamoto N. HIV-1 reproduction is inhibited by peptides derived from the N- and C-termini of HIV-1 protease. Biochem. Biophys. Res. Commun. 179:1991;847-851.
9. Zhang Z.-Y., Poorman R.A., Maggiora L.L., Heinrikson R.L., Kezdy F.J. Dissociative inhibition of dimeric enzymes. Kinetic characterization of the inhibition of HIV-1 protease by its COOH-terminal tetrapeptide. J. Biol. Chem. 266:1991;15591-15594.
10. Schramm H.J., Boetzel J., Büttner J., Fritsche E., Göhring W., Jaeger E., König S., Thumfart O., Wenger T., Nagel N.E., Schramm W. The inhibition of human immunodeficincy virus protease by 'interface peptides'. Antiviral Res. 30:1996;55-70.
11. Schramm H.J., de Rosny E., Reboud-Ravaux M., Büttner J., Dick A., Schramm W. Lipopeptides as dimerization inhibitors of HIV-1 protease. Biol. Chem. 380:1999;593-596.
12. Franciskovich J., Houseman K., Mueller R., Chmielewski J. The systematic evaluation of the inhibition of HIV-1 protease by its C- and N-terminal peptides. Bioorg. Med. Chem. Lett. 3:1993;765-768.
13. Zutshi R., Franciskovich J., Shultz M., Schweitzer B., Bishop P., Wilson M., Chmielewski J. Targeting the dimerization interface of HIV-1 protease: inhibition with cross-linked interfacial peptides. J. Am. Chem. Soc. 199:1997;4841-4845.
14. Zutshi R., Chmielewski J. Targeting the dimerization interface for irreversible inhibition of HIV-1 protease. Bioorg. Med. Chem. Lett. 10:2000;1901-1903.
15. Bouras A., Boggetto N., Benatalah Z., de Rosny E., Sicsic S., Reboud-Ravaux M. Design, synthesis, and evaluation of conformationally constrained tongs, new inhibitors of HIV-1 protease dimerization. J. Med. Chem. 42:1999;957-962.
16. Song M., Rajesh S., Hayashi Y., Kiso Y. Design and synthesis of new inhibitors of HIV-1 protease dimerization with conformationally constrained templates. Bioorg. Med. Chem. Lett. 11:2001;2465-2468.
17. Petry H, Ast O, de Rosny E, Lieder K, Jentsch KD, Hunsmann G, Goldmann C, Lüke W, Büttner J, Reboud-Ravaux M, Schramm W, Schramm HJ. Inhibition of HIV-1 replication by peptidic protease inhibitors. In: Brockmeyer NH, Brodt R, Hoffmann K, Reimann G, Stücker M, Altmeyer P, editors. HIV-Infekt. Springer; 1999. p. 63-7.
18. Billich A., Hammerschmid F., Winkler G. Purification, assay and kinetic features of HIV-1 proteinase. Biol. Chem. Hoppe Seyler. 371:1990;265-272.
19. Park S.-H., Raines R.T. Genetic selection for the dissociative inhibitors of designated protein-protein interactions. Nat. Biotech. 18:2000;847-851.
20. Cartas M., Singh S.P., Serio D., Rizvi T.A., Kalyanaraman V.S., Goldsmith C.S., Zaki S.R., Weber I.T., Srinavasan A. Intervirion display of a peptide corresponding to the dimer interface structure of protease attenuates HIV-1 replication. DNA Cell Biol. 20:2001;797-805.
21. Todd S., Anderson C.G., Jolly D.J., Craik C.S. HIV protease as a target for retrovirus vector-mediated gene therapy. Biochim. Biophys. Acta. 1477:2000;168-188.
22. Cochran A.G. Antagonists of protein-protein interactions. Chem. Biol. 7:2000;R65-R94.
23. Sluis-Cremer N., Tachedjian G. Modulation of the oligomeric structures of HIV-1 retroviral enzymes by synthetic peptides and small molecules. Eur. J. Biochem. 269:2002;5103-5111.
24. Richards A.D., Roberts R., Dunn B.M., Graves M.C., Kay J. Effective blocking of HIV-1 proteinase activity by characteristic inhibitors of aspartic proteinases. FEBS Lett. 247:1989;113-117.
25. Stryer L. The interaction of a naphthalene dye with apomyoglobin and apohemoglobin. A fluorescent probe of non-polar binding sites. J. Mol. Biol. 13:1965;482-495.
26. Jaskolski M., Miller M., Tomasselli A.G., Sawyer T.K., Staples D.G., Heinrikson R.L., Schneider J., Kent S.B.H., Wlodawer A. Structure at 2.5 Å resolution of chemically synthesized human immunodeficiency virus type 1 protease complexed with a hydroxyethylene-based inhibitor. Biochemistry. 30:1991;1600-1609.
27. Caflisch A., Schramm H.J., Karplus M. Design of dimerization inhibitors of HIV-1 aspartic proteinase: a computer-based combinatorial approach. J. Comput. Aided Mol. Des. 14:2000;161-179.
28. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23:1997;2-25.